Real-Life Effectiveness of Subcutaneous Immune Therapy with Carbamylated Monomeric Allergoids on Mite, Grass, and Pellitory Respiratory Allergy: A Retrospective Study
Authors:
- Mario Di GioacchinoMario Di Gioacchino
- Loredana Della ValleLVLoredana Della Valle
- Rocco MangifestaRMRocco Mangifesta
- Arianna LumacaALArianna Lumaca
- Francesco CipolloneFCFrancesco Cipollone
- Franco FratiFFFranco Frati
- Enrico CompalatiECEnrico Compalati
- Eralda LekliELEralda Lekli
- Etleva Qirco LolociELEtleva Qirco Loloci
- Francesca SantilliFrancesca Santilli
Open Access
- 12 December 2022
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (24) , 7384
Abstract
Background: real-life studies are encouraged to evaluate the effectiveness and safety of allergen immunotherapy (AIT). In this context, a retrospective cohort study was conducted to assess the effectiveness and safety of carbamylated monomeric allergoid subcutaneous immunotherapy (MA-SCIT), along with patient satisfaction. Methods: a total of 291 patients with rhinoconjunctivitis with or without asthma with inhalant (house dust mite, grass, and pellitory) allergies were enrolled in this study. Perceived efficacy and perceived satisfaction with MA-SCIT, symptom score by VAS, ARIA classification of rhinitis, drug consumption, number of asthma worsening episodes, and asthma symptom control were evaluated by questionnaires before, after one year, at the end of treatment, and after one or two years of MA-SCIT. Results: the overall symptom score significantly decreased over the years of MA-SCIT, irrespective of specific sensitization (p < 0.01). There was a substantial amelioration of rhinitis severity, with a significant reduction (p < 0.01) in drug use. A significant reduction was observed in the asthma symptom VAS score and asthma-worsening episodes requiring systemic steroids. None of the patients reported any severe adverse reactions. Finally, 90% of the patients reported full satisfaction with the treatment. Conclusions: the study showed that AIT with carbamylated monomeric allergoids of grass, pellitory, and mites was effective and well tolerated by patients.Keywords
This publication has 60 references indexed in Scilit:
- Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapyJournal of Allergy and Clinical Immunology, 2013
- Visual analogue scale in patients treated for allergic rhinitis: an observational prospective study in primary careClinical & Experimental Allergy, 2013
- Patient-reported outcome measures: The importance of patient satisfaction in surgerySurgery, 2009
- Effect of sublingual immunotherapy with grass monomeric allergoid on allergen-specific T-cell proliferation and interleukin 10 productionAnnals of Allergy, Asthma & Immunology, 2008
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Sublingual immunotherapy with Dermatophagoides monomeric allergoid down‐regulates allergen‐specific immunoglobulin E and increases both interferon‐γ‐ and interleukin‐10‐productionClinical & Experimental Allergy, 2006
- Safety of sublingual immunotherapy with a monomeric allergoid in very young childrenAllergy, 2004
- Monomeric chemically modified allergens: immunologic and Physicochemical characterigationAllergy, 1996
- Monomeric chemically modified allergens: immunologic and physicochemical characterizationAllergy, 1996
- PROPHYLACTIC INOCULATION AGAINST HAY FEVERThe Lancet, 1911